ReviewFrontiers in immunology2026
The hidden cost of antibiotics: microbial dysbiosis-induced SCFA imbalance and its underlying mechanisms.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics, especially broad-spectrum types, disrupt the gut microbiota by indiscriminately killing both pathogenic and beneficial bacteria, leading to dysbiosis. This dysbiosis directly contributes to an imbalance in metabolites, such as short-chain fatty acids (SCFA) produced by gut bacteria from indigestible carbohydrates. Such shifts promote the selective expansion of facultative anaerobic pathogens, particularly Proteobacteria, thereby exacerbating epithelial oxidative stress and low-grade inflammation. Simultaneously, reduced SCFA availability disrupts tight junction expression, increases intestinal permeability, and impairs immune regulation by limiting Regulatory T cell (Treg) differentiation and attenuating G protein-coupled receptor (GPCR) (e.g., Free fatty acid receptor (FFAR) 2/3) and histone deacetylase (HDAC)-dependent anti-inflammatory pathways. Furthermore, antibiotic-induced SCFA depletion impairs GPCR-mediated signaling and disrupts vagal and enteroendocrine pathways that mediate gut-brain communication. Consequences of this antibiotic-dysbiosis-SCFA imbalance cascade include short-term issues like antibiotic-associated diarrhea (AAD), as well as long-term risks such as obesity, allergies, asthma, inflammatory diseases, and even impacts on brain development in neonates. In this review, we overview the mechanistic insights of how antibiotics reshape microbiota-derived SCFA profiles and highlight the implications for host health and disease, ultimately underscoring the need for targeted strategies such as microbiota restoration and prebiotic supplementation to mitigate these hidden consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.